1,802 followers
Donanemab in early symptomatic Alzheimer’s disease Read our summary of a placebo-controlled study that assessed the effect of donanemab in people aged 60–85 years with early symptomatic Alzheimer’s disease https://t.co/zWpMNi2XUm https://t.co/ereZ5c91IB